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Introduction
Granulomatosis with polyangiitis (GPA, Wegener’s) is a
systemic vasculitis affecting mostly small vessels, typically
involving the upper respiratory tract, lungs, and kidneys.
Together with microscopic polyangiitis, eosinophilic gran-
ulomatosis with polyangiitis (Churg–Strauss syndrome),
and renal-limited vasculitis, it commonly shows circulating
antineutrophil cytoplasmic antibodies (ANCA). As such, it
is typically referred to as an ANCA-associated vasculitis [1,
2]. The pathogenesis of GPA has not been fully elucidated,
although the interaction between ANCA and neutrophils
seems pivotal in initiating and supporting an inflammatory
reaction with subsequent cytokine, complement, and endo-
thelium involvement [3]. The hallmark of the respiratory
tract pathology is granulomatous inflammation, in which the
eicosanoid derivatives play an important role. Clinical diag-
nostics often requires an invasive approach, i.e., open lung
biopsy, bronchoalveolar lavage, or bronchoscopy-guided
biopsies. Recently, a noninvasive diagnostic method of the
respiratory tract examination was introduced; namely, ex-
haled breath condensate (EBC) analysis. We have previous-
ly described a highly specific increase in 12-lipoxygenase
product (12-HETE) in EBC samples of eosinophilic with
polyangiitis patients [4]. We wondered if ascertainment of
eicosanoid profile in EBC from GPA patients could help in
noninvasive diagnostics of GPA.
Patients and methods
Patients
We enrolled 27 patients with GPA treated in the Department
of Medicine of the University Hospital, Jagiellonian
University Medical College. The control group consisted
of 30 healthy volunteers recruited from the hospital employ-
ees with similar gender distribution. GPA was diagnosed
according to the American college of rheumatology criteria,
and all patients were c-ANCA positive [5]. The Birmingham
vasculitis activity score (BVAS v.3, range 0–63 points) [6]
was used to assess activity of GPA; results above three
indicated active disease. All subjects studied gave informed
written consent to participate. The study protocol complied
with the Helsinki Declaration and was approved by the
Jagiellonian University ethics committee.
Exhaled breath condensate collection and analysis
EBC were collected with EcoScreen I Jaeger® condensing
chamber (GmbH Hoechberg, Germany) according to the
ATS/ERS recommendations [7]. Collected EBC (1–2ml with-
in 15 min) was immediately stored at −80 °C until analysis.
High-performance liquid chromatography tandem mass
spectrometry (HPLC–MS/MS; Qtrap 4000, Applied
Biosystems, Foster City, CA, USA) or gas chromatogra-
phy–mass spectrometry (GC–MS; Engine 5989B series II
Hewlett Packard, Palo Alto, CA, USA) were used for the
quantification of substances with a stable isotope dilution
method [8]. The detection levels for the eicosanoids (in
picograms per milliliter) were as previously described [8,
9], and palmitic acid (PA)—abundant in EBC—was used
for a correction of dilution factor. Eicosanoids were
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therefore expressed in picograms per microgram of PA
(in parts per million).
Lung function tests
Lung function tests were performed using the protocols
recommended by ATS/ERS guidelines [10]. Forced expira-
tory volume in 1 s (FEV1) and vital capacity (FVC) were
expressed as a percentage of predicted value.
Statistical analysis
Statistical analysis was performed using Statistica software
(StatSoft, Inc., 2011). Data are presented as the median with
interquartile range. After ascertaining the normal distribu-
tion, the comparisons of eicosanoids between the two
groups were done using the Student’s t test, Welch’s test,
or by Mann–Whitney U test. Correlation analyses were
performed using Pearson’s test or Spearman’s test as appro-
priate, with respect to data distribution. P values less than
0.05 were considered as statistically significant.
Results
The healthy controls (HC) were gender matched with the
GPA patients; however, they were younger (41.5±[26–53]
for HC and 58±[46–61] for GPA; p=0.041). In the GPA
Table 1 Eicosanoid profile in
exhaled breath condensate
(EBC) of Granulomatosis with
polyangiitis patients (Wegener’s,
GPA) and healthy controls (HC)
Median (25–75 interquartile
range) concentration of eicosa-
noid in EBC are presented as
picograms per microgram of
palmitic acid (ppm).
HC healthy controls, GPA gran-
ulomatosis with polyangiitis
(Wegener’s), HETE hydroxyei-
cosatetraenoic acid, LT leukotri-
ene, PG prostaglandin, tetranor-
PGEM tetranor-prostaglandin E
metabolite, TX thromboxane, 6-
keto-PGF1α prostacyclin me-
tabolite, 8-iso-PGF2α isopros-
tane F2α, 9a, 11b-PGF2 PGD2
metabolite
GPA HC P value
5-HETE 2.69 (1.88–3.95) 4.70 (3.28–8.54) <0.001
12-HETE 4.63 (3.46–5.99) 5.67 (3.57–8.33) NS
15-HETE 4.35 (3.14–6.09) 5.84 (3.68–9.78) 0.054
LTB4 49.09 (20.3–77.3) 16.14 (10.73–26.01) <0.001
LTC4 0.64 (0.44–1.41) 2 (0.89–4.83) <0.01
Trans-LTC4 39.67 (32.62–77.92) 194.4 (35.71–296.53) <0.01
LTD4 1.54 (0.84–1.98) 1.89 (0.78–3.94) NS
LTE4 2.37 (1.24–3.83) 2.41 (1.4–4.32) NS
Eoxin C4 0.68 (0.36–0.91) 1.06 (0.58–2.12) <0.01
Eoxin D4 0.53 (0.32–1.46) 1.47 (0.92–2.83) <0.01
Eoxin E4 1.01 (0.56–2.04) 8.08 (4.86–19.24) <0.01
Lipoxin A4 0.93 (0.47–1.64) 0.72 (0.45–1.71) NS
11-dehydro-TXB2 13.51 (10.37–15.37) 10.0 (7.71–12.31) <0.001
PGD2 2.91 (1.46–5.41) 1.89 (0.65–3.16) <0.01
9a,11b-PGF2 0.28 (0.13–0.39) 0.59 (0.37–0.87) <0.001
PGE2 2.04 (1.22–3.79) 1.75 (0.94–3.49) NS
Tetranor-PGEM 39.67 (32.62–77.92) 194.4 (35.71–296.53) <0.01
6-keto-PGF1α 13.83 (10.28–17.84) 15.71 (11.54–20.16) NS
PGF2α 0.89 (0.17–2.23) 0.69 (0.42–1.41) NS
8-iso-PGF2 α 0.48 (0.36–0.73) 0.5 (0.33–0.84) NS
Fig. 1 Values of lipoxygenase
and cyclooxygenase pathways
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group, there were 11 (40.7 %) women and 16 (59.3 %) men.
All patients in their course of the disease had positive c-
ANCA; and during the study, it was positive in 15/27
patients (55.5 %). The mean BVAS was 1 (0–7), and
18/27 patients (66 %) were in disease remission. Twenty-
one (77.8 %) patients were treated with corticosteroids, with
the mean dose of 7 mg [4–16] daily of methylprednisolone,
and 17 (63 %) were on additional immunosuppressive ther-
apy, mainly cyclophosphamide. During the course of the
disease, 23/27 patients (85 %) had documented lung in-
volvement, whereas in the time of the study, 11/27 (41 %)
patients had either characteristic for the disease lung
changes detected in x-ray or in computed tomography.
Mean FEV1% was 87 (79.9–96.2) and FVC 90.2 (82.8–
101). Eleven patients (41 %) were either present of previous
smokers similarly to the HC.
Significant differences in the EBC eicosanoid profile be-
tween GPA group and HC were observed. In the GPA group,
LTB4, PGD2, and 11-dehydro-TXB2 were elevated, whereas
5-HETE, LTC4, trans LTC4, eoxins (C4, D4, E4), 9α, 11β
PGF2α, and tetranor-PGE-M were decreased. All measured
eicosanoids values are shown in Table 1 and Fig. 1.
No correlation between clinical manifestation of the GPA
presentation, lung abnormalities, dose of oral corticosteroids,
BVAS score, or remission/exacerbation period and EBC eico-
sanoids was observed.
Discussion
In the current study, we show that the profile of eicosanoids
measured in the EBC from GPA patients differs substantially
from healthy controls. We observed increase in the concentra-
tion of LTB4 and PGD2 and concomitant decrease in eoxins,
cysteinyl leukotrienes, and PGE2 metabolite in EBC sampled
fromGPA patients. A significant elevation of leukotriene B4, a
5-lipoxygenase (5-LO) product, was reported to be associated
with the presence of anti-PR3 autoantibodies in GPA [11].
LTB4 is a potent chemoattractant and activator of neutrophils,
which produce LTB4 by themselves or by activation of macro-
phages/monocytes [12]. Interestingly, an induction of the 5-
LO pathway was not followed by an increase of other medi-
ators, e.g., 5-HETE, cysteinyl leukotrienes, and eoxins. It may
be explained by a lack of expression of leukotriene-C4 syn-
thase by mature neutrophils and activation-dependent translo-
cation of 5-LO and subsequent switch in substrate specificity
[13]. LTB4 is an autocrine positive feedback signal for neu-
trophils, which is accompanied by a selective increase of some
cyclooxygenase products: 11-dehydro-thromboxane B2 and
prostaglandin D2—both with known effects on the bronchi
and vasculature. The latter (PGD2) is a potent antiinflamma-
tory mediator, and some studies suggest that it plays a major
role as a signaling molecule between alveolar/epithelial cells
and infiltrating neutrophils, resulting in inhibition of the in-
flammatory process (e.g., in acute lung injury) [14]. It is
furthermore probable, as PGDR (PGD2 receptor) gene has
been found to be upregulated in neutrophils stimulated in vitro
with native anti-PR3 autoantibodies [15]. However, this over-
production of proinflammatory prostanoids was not counter-
balanced by PGE2, or its metabolite—tetranor-PGEM, sug-
gesting decreased biosynthetic capacity of PGE2 in prostaglan-
din pathway. Our findings support the hypothesis of a specific
type of neutrophil ANCA priming, which results in a distinct
pattern of proinflammatory lipid mediators in GPA [16].
No differences in the eicosanoid profile were noted between
the active and remission phase of the disease. In our opinion,
this could be due to the fact the most of the patients were on
systemic corticosteroids and additional immunosuppressive
therapy. Other factor that may influence this lack of correlation
between the disease activity and eicosanoid profile is that lung
assessment in GPA patients is based on radiographic x-ray or
computed tomography findings that may not reflect the ongo-
ing inflammatory process in the respiratory tract.
We are aware that this is just a preliminary study, and that it
has several limitations, such as the sample size of the studied
group. Also, due to low levels of measured eicosanoids, that
so far need a sophisticated and not widely available analytical
platform based on mass spectrometry, these findings may not
find its way to clinical practice in the nearest future.
Nevertheless, sampling of a noninvasive material (EBC)
of the bronchial epithelial lining fluid in GPA patients gives
insight into a specific pattern of arachidonic acid pathway
metabolites reflecting the presence of primed neutrophils.
These findings may help to better understand the inflamma-
tory process in the GPA patients; and maybe, together with
the circulating ANCA status, could discriminate for GPA
and perhaps guide future therapies.
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